GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

eFFECTOR Therapeutics EFTR · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 6 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

—

FY2019FY2023

Net income

−$35.8m

FY2019FY2023

Free cash flow

−$29.6m

FY2019FY2023

Shareholders' equity

−$5.8m

FY2019FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019
Revenue—$3.6m$1.4m$42.0m—
Gross profit−$111,000$3.5m$1.4m$42.0m−$307,000
Research and development$22.9m$23.3m$20.0m$21.8m$23.6m
Operating income−$33.8m−$32.4m−$31.9m$15.8m−$28.6m
Net income−$35.8m−$12.9m$15.8m$14.2m−$29.7m
Diluted earnings per share-13.41-7.779.7823.74-11.14

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019
Total assets$20.5m$29.1m$54.1m$16.7m$5.1m
Cash and short-term investments$18.4m$26.3m$49.7m$15.2m$3.4m
Total liabilities$26.3m$25.2m$36.8m$148.9m$18.9m
Debt$20.5m$20.3m$20.0m$13.0m$15.2m
Shareholders' equity−$5.8m$3.9m$17.3m$979,000−$13.8m
Shares outstanding3m2m2m1m3m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019
Cash from operations−$29.6m−$25.9m−$24.9m$13.8m−$27.6m
Capital spending−$97,000−$192,000−$42,000−$154,000−$4,000
Free cash flow−$29.6m−$26.1m−$24.9m$13.7m−$27.6m

Latest quarters

By quarter end

Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022
Revenue—$162,000———$675,000$867,000$2.0m
Gross profit−$28,000$132,000−$26,000−$27,000−$28,000$648,000$849,000$2.0m
Operating income−$8.4m−$8.6m−$8.3m−$7.9m−$9.5m−$8.7m−$9.3m−$7.9m
Net income−$8.8m−$9.1m−$8.3m−$8.4m−$10.0m−$9.3m−$9.6m−$6.9m
Diluted earnings per share-3.31-3.42-3.11-3.13-3.75-5.57-5.75-4.16
Cash from operations−$7.0m−$5.0m−$7.0m−$8.0m−$7.0m−$6.0m−$8.0m−$4.0m
Total assets$27.1m$20.5m$20.2m$26.9m$21.9m$29.1m$36.7m$43.5m
Cash and short-term investments$25.4m$18.4m$17.8m$25.0m$19.0m$26.3m$33.0m$41.0m
Debt$20.1m$20.5m$20.5m$20.4m$20.3m$20.2m$20.1m$20.1m
Shareholders' equity$827,000−$5.8m−$4.0m$2.6m−$4.8m$3.9m$11.6m$19.6m

Share price return

Finished calendar years

20252024202320222021
Return40400%-100%-5%-95%-32%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 12 Jan 2024
  • 1-to-1 reverse split · 26 Aug 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.